

WHAT IS CLAIMED IS:

1. A pharmaceutical stable aqueous formulation comprising 10-100 mg/ml of an anti-CD47 antibody;

and pharmaceutically acceptable excipients comprising a buffer at a concentration of 5-20 mM; at least one stabilizer, and a surfactant, wherein the formulation has a pH of from about pH 4-6.5.

2. The formulation of claim 1, wherein the buffer is present at a concentration of from 10 to 15 mM.

3. The formulation of any of claims 1-2, wherein the buffer in the formulation is acetate buffer or histidine buffer.

4. The formulation of claim 3, wherein the buffer is acetate buffer.

5. The formulation of any of claims 1-4, where the pH is from pH 4 to pH 6.5.

6. The formulation of claim 5, where the pH is from pH 4.7 to pH 5.3.

7. The formulation of claim 5, where the pH is from pH 4.9 to pH 5.1.

8. The formulation according to any of claims 1-7, wherein the stabilizer is sorbitol at a concentration of from 2.5% to 10%.

9. The formulation according to any of claims 1-7, wherein the stabilizer is sucrose at a concentration of from 2.5% to 10%.

10. The formulation according to any of claims 1-7, wherein the stabilizer is trehalose at a concentration of from 2% to 12%.

11. The formulation according to any of claims 1-7, wherein the stabilizer is NaCl at a concentration of from 100-200 mM.

12. The formulation according to any of claims 1-10, wherein the surfactant is polysorbate 20, polysorbate 80, or pluronic F68.

13. The formulation of claim 11, wherein the surfactant is polysorbate 20 at a concentration of surfactant of from about 0.005% to about 0.05%.

14. The formulation of any of claims 1-13, wherein the formulation is stable at a temperature of from about 2° C to about 8°C. for at least 12 months.

15. The formulation of any of claims 1-13, wherein the formulation is stable at a temperature of from about 2° C to about 8°C for at least 16 weeks.

16. The formulation of claim 15, wherein the anti-CD47 antibody in the formulation retains at least 50% of its biological activity after storage.

17. The formulation of any of claims 1-16, wherein the anti-CD47 antibody in the formulation is a full-length antibody.

18. The formulation of claim 17, wherein the antibody comprises a human IgG4 constant region sequence.

19. The formulation of claim 17 or 18, wherein the antibody is a humanized antibody comprising an HCDR1 region comprising of sequence (SEQ ID NO: 1), an HCDR2 region comprising of sequence (SEQ ID NO: 2), an HCDR3 region comprising of sequence (SEQ ID NO: 3), an LCDR1 region comprising of sequence (SEQ ID NO: 4), an LCDR2 region comprising of sequence (SEQ ID NO: 5), and an LCDR3 region comprising of sequence (SEQ ID NO: 6).

20. The formulation according to any of claims 1-19, wherein the antibody is magrolimab.

21. A pharmaceutically acceptable, stable liquid formulation comprising 10-20 mg/ml magrolimab; 10 mM acetate buffer; 5% w/v sorbitol; 0.01% - 0.04% polysorbate 20 at a pH of from 4.5 – 5.5.

22. A pharmaceutically acceptable, stable liquid formulation comprising 10-20 mg/ml magrolimab; 10 mM acetate buffer; 9% w/v sucrose; 0.01% - 0.04% polysorbate 20 at a pH of from 4.5 – 5.5.

23. A pharmaceutically acceptable, stable liquid formulation comprising 10-20 mg/ml magrolimab; 10 mM acetate buffer; 9% w/v trehalose; 0.01% - 0.04% polysorbate 20 at a pH of from 4.5 – 5.5.

24. An article of manufacture comprising a unit dose of a formulation according to any of claims 1-23.

25. A-Use of an effective dose of an antibody formulation according to any of claims 1-23 in the manufacture of a medicament ~~method-orfor~~ treating an individual in need thereof ~~by administering an effective dose of an antibody formulation according to any of claims 1-23.~~